Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands

Clinical Therapeutics/Volume 39, Number 2, 2017

Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands Lisa A. de Jong, MSc1; Evgeni Dvortsin, MSc1; Kristel J. Janssen, PhD2; and Maarten J. Postma, MSc, PhD1,3 1

Unit of PharmcoEpidemiology and PharmacoEconomics (PE2), University of Groningen, Groningen, the Netherlands; 2Bristol-Myers Squibb, Utrecht, the Netherlands; and 3Institute for Science in Healthy Aging & healthcaRE (SHARE), University Medical Center Groningen (UMCG), Groningen, the Netherlands

ABSTRACT Purpose: Low-molecular weight heparin (LMWH) followed by vitamin K antagonists (VKAs) are the current standard treatment of acute venous thromboembolism (VTE) and prevention of recurrent VTE. The direct oral anticoagulant apixaban was recently found noninferior in efficacy and superior in preventing major bleeding compared with LMWH/VKAs in the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial. The objective of this study was to calculate the cost-effectiveness of apixaban compared with LMWH/VKA in the treatment of acute VTE and prevention of recurrent VTE in the Netherlands. Methods: A Markov model was designed to simulate a cohort of 1,000 VTE patients receiving either apixaban or LMWH/VKA. Transition probabilities, costs, and utilities were obtained from the AMPLIFY trial and other literature. The incremental costeffectiveness ratio (ICER) was calculated from the societal perspective; therefore, the model included both direct (inside and outside the health care sector) and indirect costs. In the univariate and probabilistic sensitivity analyses (PSAs) the robustness of the results was tested, and various additional scenario analyses were conducted. Findings: In the base-case analysis, apixaban saved €236 and 0.044 quality-adjusted life years (QALYs) and 0.039 LYs were gained compared with LMWH/ VKA. In the univariate sensitivity analysis the model appeared to be robust. The results of 2,000 iterations in the PSA found that the probability of apixaban being cost-effective at a willingness-to-pay threshold of €20,000/QALY was 100% and cost-saving was

288

94%. The scenario of 18-month treatment duration was the only scenario not indicating cost-savings with an ICER of €425/QALY. Implications: In acute anticoagulation use apixaban was found to be cost-saving. A longer anticoagulation period (18 months) resulted in a higher difference in drug costs, indicating a higher ICER. The costeffectiveness of long-term or life-long use should be examined in future research. (Clin Ther. 2017;39:288–302) & 2017 Elsevier HS Journals, Inc. All rights reserved. Key words: apixaban, cost-effectiveness, direct oral anticoagulant, venous thromboembolism.

INTRODUCTION Deep vein thromboembolism (DVT) and pulmonary embolism (PE) are collectively known as venous thromboembolism (VTE). DVT is a blood thrombus mostly seen in the calf veins, and PE is the result of a free clot causing obstruction in the pulmonary veins. Diagnosis of VTE is based on the symptoms and a D-dimer test, and risk factors (eg, recent surgery, smoking) can confirm the suspicion.1 In 2014 a total of approximately 60,000 VTE patients, including nearly 19,000 new patients, were monitored by the Dutch Thrombotic Service.2 Of these patients 56% were treated for (recurrent) DVT and 44% for (recurrent) PE.2 In general practice, the incidence of DVT and PE is respectively 0.5 to 1.5 and Accepted for publication December 13, 2016. http://dx.doi.org/10.1016/j.clinthera.2016.12.012 0149-2918/$ - see front matter & 2017 Elsevier HS Journals, Inc. All rights reserved.

Volume 39 Number 2

L.A. de Jong et al. 0.2 per 1,000 patients per year.1 The incidence of suspected PE, estimated by a survey among Dutch pulmonologists and internists, was 2.6 per 1,000 inhabitants per year, of which about 30% actually had PE.3 The recurrence of VTE is 7% per year, and 30% of the patients experience a recurrent VTE (RecVTE) event within 8 years.1,4 The occurrence of VTE imposes a decreased healthrelated quality of life and increased costs due to extending hospital stays, additional hospitalizations, and increased case-fatality and mortality rates in patients with PE.5,6 Although VTE is treated as an acute event, it is associated with an increased risk of recurrence and chronic complications.1 Postthrombotic syndrome (PTS) can develop after chronic venous valve insufficiency caused by DVT. A rare delayed complication of PE is chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is caused by arterial lung obstruction, which can induce heart failure.1 The current treatment procedure of acute VTE in the Netherlands consists of a minimum of 5 days of low-molecular weight heparin (LMWH), followed by at least 3 months of anticoagulation with a vitamin K antagonist (VKA; eg, warfarin, acenocoumarol, phenprocoumon). Some high-risk patients receive anticoagulants as prophylaxis for a longer period.3 Although the anticoagulation effect of VKA is considered strongly effective, the use is limited because of increased bleeding risks, a narrow therapeutic range, and the interactions with food and other drugs. Because of the narrow therapeutic range, monitoring of the international normalized ratio (INR) of the prothrombin time of the patients is required. In the Netherlands the INR range for VTE is 2.0 to 3.5, and the monitoring is conducted by specialized thrombotic services.1–3 Lately, direct oral anticoagulants (DOACs) have been developed, which address most of these issues. Next to dabigatran, rivaroxaban, and edoxaban, apixaban is one of the representatives of this group of DOACs. Although VKAs inhibit several coagulation factors indirectly, apixaban is a specific factor Xa inhibitor, enabling a more predictable therapeutic effect.7 Next to this, treatment with apixaban does not require INR monitoring and LMWH use. The AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial reported the effectiveness and

February 2017

safety profile of apixaban compared with warfarin in the acute (6 months) treatment of VTE.8 The trial found noninferiority of apixaban to warfarin in the recurrence VTE or VTE-related death (VTEdie). Moreover, apixaban treatment was associated with a significant reduction of major bleeding (MB) and clinically relevant non-MB. In the AMPLIFY-EXT (for Extended Treatment of Venous Thromboembolism) trial an extended treatment of an additional 6 months of therapy of apixaban in two different doses (2.5 and 5.0 mg) was compared with placebo for the prevention of VTE.9 Apixaban treatment was found to reduce the risk of RecVTE and VTEdie, without increasing bleeding risks. With increasing importance of cost-effectiveness in decision making, the consequences for the quality of life and costs associated with apixaban compared with LMWH/VKA need to be considered. This is in particular the case in Western countries, such as the Netherlands.10 The aim of this study is to estimate the cost-effectiveness of apixaban compared with LMWH/VKA in the acute treatment and secondary prevention of VTE in the Netherlands.

METHODS Decision Model The cost-effectiveness of apixaban compared with the current standard treatment of LMWH/VKA was calculated using a cohort-based Markov model designed in Excel (Microsoft, Redman, Washington; 2013).11,12 A cohort of 1,000 patients who had just experienced a VTE event was followed in the model. The population had an average starting age of 57 years and 59% were male, based on the patient characteristics of the AMPLIFY trial (see Supplemental Table SI in the online version at http:// dx.doi.org/10.1016/j.clinthera.2016.12.012).8 In the Markov model, the patients move through 12 health states: index DVT, index PE, RecVTE (RecPE or RecDVT), VTEdie, MB, CRNM bleed, CTEPH, PTS, treatment discontinuation (TxDiscontinue), other death, and no event. The pathways that specify the transitions among the different health states are detailed in Figure 1. A cycle length of 3 months was used, and in each cycle only one event was allowed to occur. The model used half-cycle corrections.11 Specific event probabilities were based on the AMPLIFY and AMPLIFY-EXT trials and

289

Clinical Therapeutics RecPE Alive RecVTE or VTEdie RecDVT 1-(Background Mortality) VTEdie

}

GO to Index PE GO to Index PE Go to Death

Index PE Fatal MajBleed

Note: SUM(RecPE, RecDVT, VTEdie)=100%

GO to Death

MajBleed Nonfatal IC Bleed Nonfatal MajBleed 1-(Fatal MajBleed)

Nonfatal EC Bleed 1-(Nonfatal IC Bleed)

Go to Post IC Bleed (Absorption)

TxDiscontinue

Go to Death

Go to Index PE 2nd Line

No TxDiscontinue 1-(TxDiscontinue) CRNM

Go to Index PE

Go to Index PE

Fatal CTEPH

Go to Death

CTEPH Nonfatal CTEPH 1-(Fatal CTEPH) Other TxDiscontinue

Go to Post CTEPH (Absorption)

Go to Death

Go to index PE 2nd Line

No Event

1-SUM(RecVTE, VTEdie, MajBleed, CRNM, CTEPH, Other TxDiscontinue) Go to Index PE Background Mortality Index DVT

Go to Death

Similar to Index PE logic,except if patient experiences RecPE, then they go to Index PE

Figure 1. Schematic structure of the cohort-based Markov model. CRNMB ¼ clinically relevant non-major bleed; CTEPH ¼ chronic thromboembolic pulmonary hypertension; DVT ¼ deep venous embolism; EC ¼ extracranial, IC ¼ intracranial; MB ¼ major bleed; PE ¼ pulmonary embolism; Rec ¼ recurrent; TxDiscontinue ¼ treatment discontinuation; VTEdie ¼ venous thromboembolismrelated death.

previously published articles.8,9 In these trials warfarin, which is the worldwide most used VKA, was compared with apixaban. In the Netherlands the most used VKAs are acenocoumarol and phenprocoumon. Because the Dutch reimbursement authorities presume the efficacy and safety profile of warfarin is similar to acenocoumarol and phenprocoumon, these risks found in these trials could also be applied in a model specific for the Netherlands. Patients who just experienced a PE or DVT entered the model in the state index PE or index DVT. The distribution over PE and DVT was based on the AMPLIFY trial.8 Shortly after entering the index state, patients received an initial treatment of 6 months of anticoagulation with either apixaban or 7 days of LMWHs, followed by VKA.8 Subsequently, the patients were exposed to risks of RecVTE events, bleeding events, chronic consequence CTEPH, TxDiscontinue, and death from other causes (background mortality). On the recurrence of VTE during the initial anticoagulation treatment, the current treatment was extended by 6 months. In case

290

RecVTE occurred after the initial treatment, the patients were signed up for a 6-month treatment with LMWH/VKA in the model.9 RecVTE was divided into VTEdie, nonfatal RecPE, and nonfatal RecDVT because of differing effects on health outcomes, costs, and rates of mortality.1,4 After a RecPE or RecDVT, patients move to the states index PE and index DVT, respectively. Consequences associated with PE on health outcomes (Table I) and costs are considered more serious than those of DVT.1,3,4 Therefore, patients who had experienced a PE in the past return to the state index PE after a RecVTE, regardless of the origin (PE or DVT). As a result, patients who experienced both DVT and PE have assigned risks of CTEPH and PTS in the model. Once patients developed the chronic complication CTEPH, they moved to a post-CTEPH state with higher mortality risks and could not move to other states except death. MB could be fatal or nonfatal. In the case of nonfatal MB, a patient had either an intracranial (IC) bleeding or an extracranial (EC)

Volume 39 Number 2

L.A. de Jong et al.

Table I. Base-case transition probabilities per specific time period with the associated ranges and distributions used in the probabilistic sensitivity analysis. Transition Probability Recurrent VTE and VTE-related death Apixaban 0–3 months Apixaban 3–6 months LMWH/VKA 0–3 months LMWH/VKA 3–6 months Distribution of PE, DVT, and VTE-related death 0–6 months VTE-related death Recurrent PE Recurrent DVT Cumulative incidence of risk recurrent VTE after treatment cessation 0–1 year 1-3 years 3–5 years 5–10 years Major bleeding Apixaban 0–3 months Apixaban 3–6 months LMWH/VKA 0–3 months LMWH/VKA 3–6 months Proportion of fatal major bleeding among major bleeding and nonfatal IC bleeding among nonfatal major bleeding Fatal major bleeding Nonfatal IC bleeding Risk of CRNM bleeding Apixaban 0–3 months Apixaban 3–6 months LMWH/VKA 0–3 months LMWH/VKA 3–6 months Bleeding risk adjustment factor major bleeding and CRNM bleeding (per decade) Risk of treatment interruption after non-IC bleeding (14 days) Risk of treatment interruption after CRNM bleeding (2 days) Risk of other treatment discontinuation (unrelated to discontinuation due to the events modelled) Apixaban 0–6 months LMWH/VKA 0–6 months Annual risk of CTEPH in PE patients

Value (95% CI/range)

Distribution

Source

β β β β

Agnelli Agnelli Agnelli Agnelli

Fixed Fixed Fixed

Agnelli et al8 Agnelli et al8 Agnelli et al8

0.0110 (0.0950–0.1250) 0.1960 (0.1750–0.2170) 0.2910 (0.2630–0.3190) 0.3990 (0.3540–0.4440)

β β β β

Prandoni Prandoni Prandoni Prandoni

et et et et

0.0041 (0.00169–0.00653) 0.0015 (0.00003–0.00296) 0.0141 (0.00966–0.01857) 0.0041 (0.00168–0.00650)

β γ β β

Agnelli Agnelli Agnelli Agnelli

al8 al8 al8 al8

0.1346 (0.1128–0.1580) 0.1397(0.1160–0.1652)

β β

Linkins et al14 Linkins et al14

0.0265 (0.0202–0.0326) 0.0120 (0.0078–0.0161) 0.636 (0.0544–0.0728) 0.0164 (0.0116–0.0212) 1.970 (1.7900–2.1600)

β β β β Log normal

Agnelli et al8 Agnelli et al8 Agnelli et al8 Agnelli et al8 Ariesen et al15

0.4727 (0.3434–0.6039)

β

Agnelli et al8

Fixed

Assumption

β β β

Agnelli et al8 Agnelli et al8 Miniati et al16

0.0171 (0.01220–0.02200) 0.0048 (0.00220–0.00750) 0.0214 (0.01600–0.02690) 0.0048 (0.00220–0.00750)

0.2154 0.3769 0.4077

1.0000

0.0487 (0.0405–0.0568) 0.0521 (0.0437–0.0605) 0.0125 (0.0003–0.0246)

et et et et

et et et et

al8 al8 al8 al8

al13 al13 al13 al13

(continued)

February 2017

291

Clinical Therapeutics

Table I. (continued). Transition Probability 5-year risk of severe PTS in DVT patients Mortality risks, HR Index DVT Index PE Post-IC bleed Post-CTEPH

Value (95% CI/range)

Distribution

Source

0.0812 (0.5000–1.0000)

β

Prandoni et al17

4.41 (3.63–5.36) 4.41 (3.63–5.36) 2.60 (2.20–5.60) 1.3 (0.98–1.73)

γ γ γ γ

Flinterman et al18 Flinterman et al18 Prandoni et al19 Ng et al20

CRNM ¼ clinically relevant non-major; CTEPH ¼ chronic thromboembolic pulmonary hypertension; DVT ¼ deep venous thromboembolism; HR ¼ hazard ratio; IC ¼ intracranial; LMWH ¼ Low Molecular Weight Heparin; PE ¼ pulmonary embolism; PTS ¼ post-thrombotic syndrome; VKA ¼ Vitamin K Antagonist; VTE ¼ venous thromboembolism.

bleeding. On the occurrence of an IC bleeding, patients moved to a post-IC bleeding state with higher mortality risks and could not move to other states, similar to the post-CTEPH state. After patients experienced a nonfatal non-IC bleeding or a CRNM bleeding, they returned to the initial index state. Next to the TxDiscontinue due to non-fatal EC bleeding (Figure 1), TxDiscontinue unrelated to bleeding events was modelled explicitly. Because of TxDiscontinue patients move to VTE off treatment, in which their risks were updated to no treatment.9 A second-line treatment, for example with aspirin, is not specified by clinical guidelines in the Netherlands; therefore, it was not included in the model.1,3 The outcome of the economic evaluation is the incremental cost-effectiveness ratio (ICER) of apixaban compared with LMWH/VKA for acute treatment and prevention of VTE. The effectiveness measures are expressed in terms of the numbers of avoided VTE or bleeding events, life years (LYs), and quality-adjusted LYs (QALYs).

Transition Probabilities The transition probabilities in the model for patients treated with apixaban or LMWH/VKA in the first 6 months were obtained from the AMPLIFY trial8 and previously published articles13–20 (Table II). The risks of VTEdie and RecVTE, MB, and clinically relevant non-MB were considered to be time dependent, with risks presented for 3-month intervals. The distribution of RecPE, RecDVT, and VTEdie was based on pooled estimates of the clinical trials (AMPLIFY and AMPLIFY-EXT) and was

292

assumed to be equal across treatments.8,9 After treatment cessation, lifetime risk of RecVTE was calculated from the cumulative 10-year incidence at 39.9% found by Prandoni et al.13 The absolute risks of MB were obtained from the AMPLIFY trial.8 The distribution of the nature of the bleeding was based on a study by Linkins et al14: 13.46% of the MBs were fatal and 13.97% were IC bleedings. The residual MBs were assumed to be EC, but no distinction was made in the origin of the EC bleedings. Patients with nonfatal IC bleeding moved to a post-IC bleeding state and were assigned higher mortality rates.18 EC bleeding was assumed to have no effect on patients’ rate of mortality. Only patients in the health state PE were exposed to the risk of CTEPH, which is assumed to be equal across treatments. Once a patient moved to the postCTEPH state, they discontinued the treatment permanently and were assigned higher mortality rates.19 The risk of PTS, obtained from a prospective study by Prandoni et al,17 was applied to patients in index DVT and patients in index PE who had experienced a DVT. The model assumed a 5-year risk of severe PTS of 8.1% among patients with DVT. Only the incidence of severe PTS was applied to the model, because it was assumed that mild PTS did not affect the costs and health outcomes of the patients. The background mortality was obtained from Statistics Netherlands.21 Patients in the index, postIC bleeding, and post-CTEPH states were assigned higher mortality rates by applying corresponding hazard ratios obtained from previously published articles.18–20

Volume 39 Number 2

L.A. de Jong et al.

Table II. Costs applied in the Markov model. Resources Medication Apixaban (daily) Introduction period (20 mg/d) Long-term period (10 mg/d) Extended treatment (2.5 mg/d)* LMWH: nadroparin 19000 IU/mL, 0.8 mL (daily) VKA (daily) Introduction period (3.2 mg) Long-term period (2.2 mg) Administration and monitoring costs Patient education/instruction to self-inject LMWH administration by homecare nurse INR monitoring visit Event-related costs PE/DVT inpatients Diagnosis and treatment (day admission) PE/DVT outpatients Doppler ultrasound CT angiography Echocardiogram D-Dimer test GP visit Other event-related costs IC bleeding Acute care Long-term maintenance CTEPH Acute care (diagnosis and 56.8% of patients PEA surgery) Long-term maintenance Non-IC major bleeding CRNM bleeding (one GP visit) Severe PTS Fatal major bleeding

Fatal event due to CTEPH

Average Cost, € (2015)

Range, €

4.60 2.3 2.15 9.37

Fixed Fixed Fixed Fixed

Z-index30 Z-index30 Z-index30 Z-index30

0.06 0.04

Fixed Fixed

Z-index30 Z-index30

71.32 19.05 11.58

53.49–89.15 14.29–23.81 8.69–14.48

Source

NZA31 NZA31 FNT2, NZA31

566.23

424.67–707.79 NZA31

41.09 204.25 41.09 2.45 29.20

30.82–51.36 153.19–255.31 30.82–51.36 1.84–3.06 21.90–36.50

20,489 591.70

14,907–28,161 Stevanović et al32 43.42–813.46 Stevanović et al32

4,271

2,136–6,407

NZA31 NZA31 NZA31 NZA31 NZA31

NICE33,34

253.01 5,036 30.72

126.51–379.53 NICE33,34 3,664–6,921 Ten Cate-Hoek et al35 23.04–38.40 Ten Cate-Hoek et al35

447.24 20,489

313.07–581.41 Ten Cate-Hoek et al35 14,907–28,161 Assumption: costs are equal to acute care costs 2,136–6,407 Assumption: costs are equal to acute care costs

4,271

(continued)

February 2017

293

Clinical Therapeutics

Table II. (continued). Resources

Average Cost, € (2015)

VTE-related death

566.23

Range, €

Source

396.36–736.10 Assumption: costs are equal to acute care costs36-39

CT ¼ computed tomography; CRNM ¼ clinically relevant non-major; CTEPH ¼ chronic thromboembolic pulmonary hypertension; DVT ¼ deep venous thromboembolism; FNT ¼ Federation Dutch Thrombotic Services; GP ¼ general practice; IC ¼ intracranial; INR ¼ international normalized ratio; LMWH ¼ low-molecular weight heparin; NICE ¼ National Institute for Health and Care Excellence; NZA ¼ Nederlandse Zorgautoriteit; PE ¼ pulmonary embolism; PEA ¼ pulmonary endarterectomy; PTS ¼ post-thrombotic syndrome; VKA ¼ vitamin K antagonist; VTE ¼ venous thromboembolism. * This variable was only used in the scenario analysis.

Utilities The utilities used in the Markov model are shown in Supplemental Table SII, with the corresponding systematic literature review in a PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses) flow diagram shown in Supplemental Figure S1 (in the online version at http://dx.doi.org/ 10.1016/j.clinthera.2016.12.012).22–25,29 All patients were assigned a baseline utility, which was updated on the occurrence of a non-fatal IC bleeding or CTEPH. Utility decrements associated with PE, DVT, non-IC bleeding, CRNM bleeding, and severe PTS were subtracted from the baseline utility. The decrement durations, specific to each event, were based on previously published articles.26–28 While on treatment, utility decrements reflecting the use of apixaban or LMWH/VKA were applied.

Costs The costs included in the Markov model are summarized in Table II. A PRISMA flow diagram for the systemic cost data collection is presented (see Supplemental Figure S2). After the first year, costs and health outcomes were discounted by 4% and 1.5% per annum, respectively.10 Direct costs inside the health care sector included drug, administration, monitoring, and event-related costs. Drug costs for LMWH, VKA, and apixaban were derived from the official Dutch pricelist (Z-index).30 Costs of apixaban were based on a 7-day introduction dose of 20 mg, a long-term dose of 10 mg/d during the first 6 months after dose introduction, and an extended dose of 2.5 mg.1,30 The price of LMWH was based on the

294

price of nadroparin, because this is the most used LMWH in the Netherlands.2 For nadroparin, the dose was assumed at 171 IE/mL per kilogram.40 For a mean weight of 84.6 kg the 0.8 mL 19,000 IE/mL syringe was closest to this recommended daily dosage.40 The price of VKA was based on the average use of acenocoumarol and phenprocoumon (77.1% and 22.9%, respectively) in the Netherlands.2,30 The 7-day introduction and long-term dosing consisted of 3.2 mg and 2.2 mg, respectively.1,3 The administration and monitoring costs for the LMWH/VKA treatment were based on information provided in the annual medical report of the Dutch Federation for Thrombotic Services of 2014.2 For the administration of LMWH, the costs of patient education was added for the 6.7% of the patients who were trained to self-inject. For the remaining 93.3% of the patients, the cost of 30 minutes of home care was applied for 7 days.36,41 The cost of the INR monitoring visits was based on the annual cost of €230 divided by the average number of 20.8 visits.2,36 Event-related acute care costs were obtained from previous publications10,13,32,35 and Dutch prices.31 Long-term costs were assigned to patients surviving PTS, CTEPH, or IC-bleeding. Hospital costs were calculated with the assumption that 40% of the patients were treated in general hospitals and 60% in academic hospitals; 8% of the DVT patients and 85% of the PE patients were treated as inpatients (Key Opinion Leader).42 The Key Opinion Leader is a medical professor in one of the University Medical Centers in the Netherlands with 420 years of experience in the diagnosis and treatment of VTE.

Volume 39 Number 2

L.A. de Jong et al. Because most PE patients are treated as an inpatient for a duration of 3.5 days, the number of days in the hospital was subtracted from the number of days they needed help with injections. Direct costs outside the health care sector were included for travel expenses to the hospital or thrombosis center and were calculated based on a distance of 14 km (7 km one way), according to the Dutch Cost Manua.36 Travel expenses were calculated as the mean of transportation costs by taxi, public transport, and car. Indirect costs included productivity losses due to the burden of VTE. The friction cost method was used to calculate the indirect costs, by applying a friction period of 23 weeks as described in the Dutch costs manual.36 Costs were analysed from a societal perspective and therefore the model included both direct (inside and outside the health care sector) and indirect costs. The indirect costs included productivity losses and traveling expenses. All relevant costs from a societal perspective were included and were corrected for inflation to August 2015.10,12,43

Sensitivity Analysis Sensitivity analyses were performed on key input variables of the model such as patient characteristics, transition probabilities, utilities, and costs. In the univariate sensitivity analysis the variables were individually varied over their 95% CI, and when the 95% CI was unavailable, the variables were assumed to follow a log-normal distribution with a relative SD of 0.25.12 The distributions used for the variables in the model were β and γ for the transition probabilities, log normal, or β or γ for relative risks (RRs), β for QALYs, and γ or log normal for costs. The impact of these varying variables on the incremental costs and QALYs were presented in tornado diagrams. A total of 87 uncertain variables were validated, and only the 15 most influencing variables were presented in the tornado diagrams, because the other variables had no observed difference in costs or QALYs. PSAs, from societal and health care payer perspectives, were conducted to account for variability in outcomes due to uncertainty in input variables. The ICER was repeatedly calculated while variating the key input variables simultaneously within their ranges. The results of 2,000 calculated ICERs were plotted in a cost-effectiveness plane.

February 2017

Scenario Analyses In total 6 scenarios were conducted to determine the effect on the ICER of relevant differing circumstances. Dutch guidelines state a treatment of 3 to 6 months for patients with an acute VTE event, and patients with RecVTE can receive treatment extension based on an expert’s opinion.1,3,42 In scenario 1 a treatment period of 3 months was applied to the model, and in scenario 2 the treatment consisted of 6 months of anticoagulation plus an extended anticoagulation period of 12 months. In scenario 3 the treatment-specific bleeding distributions (fatal/nonfatal IC) were based on the results found in the AMPLIFY trial.8 The average time in therapeutic range (TTR) in the AMPLIFY trial was 61%.8 Because of strictly carried out INR monitoring by specific Dutch thrombotic services, the TTR for Dutch patients who just received VKAs was 60.6% to 68.2%.2 In the scenario analysis the RRs for LMWH/VKA of the third quartile of the AMPLIFY population (INR, 59.1%–68%) were used (scenario 4). Scenario 5 excluded the disutilities associated with anticoagulation use. Finally, scenario 6 reflected the ICER from a health care payers’ perspective. Input variables used in the scenario analyses are summarized (see Supplemental Table SIII).

RESULTS In a cohort of 1,000 VTE patients, apixaban treatment averted 2 RecVTEs/VTEdies, 12 MBs, 38 CRNM bleeds, and 7 cases of TxDiscontinue compared with LMWH/VKA treatment (Table III). The number of observed CTEPH and PTS events are comparable for both treatments. Averted events result in a health gain of 0.044 QALYs and 0.039 LYs per patient for apixaban treatment compared with LMWH/VKA. Apixaban treatment increases anticoagulation and administration costs, and decreases the total event-related costs compared with LMWH/VKA. The treatment with apixaban was found to be cost-saving compared with LMWH/ VKA treatment (€8,178 vs €8,414) (Table IV).

Sensitivity Analysis The results of the univariate sensitivity analysis are presented in the tornado diagrams in Figures 2 and 3, reflecting the impact of the uncertainties of the key input variables of the incremental costs and QALYs, respectively. The uncertainty around apixaban unit

295

Clinical Therapeutics

Table III. Outcomes of the simulation of the hypothetical cohort of 1,000 patients diagnosed with index PE or DVT receiving apixaban or VKA: number of VTE, bleeding, and other events and the related costs per patient (discounted). Apixaban Variable Index VTE Recurrent VTE and VTE-related death VTE-related death Nonfatal recurrent PE Nonfatal recurrent DVT Total Major bleeds Fatal Nonfatal IC bleed Nonfatal EC bleed Total CRNM bleed CTEPH Treatment discontinuation Anticoagulant and administration costs Monitoring costs

Events, n

LMWH/VKA

Costs/Patient, €

Events, n

Costs/Patient, €

1,000

929

1,000

329

77 159 393 629

438 1692 207

77 160 394 630

443 1,697 207

18 16 99 132 644 34 49 — —

12,970 19,823 3,203

19 17 107 144 682 34 56 — —

14,031 21,899 3,387

20 7,976 — 509 59

20 7,963 — 285 199

CRNM ¼ clinically relevant non-major; CTEPH ¼ chronic thromboembolic pulmonary hypertension; DVT ¼ deep venous thromboembolism; IC ¼ intracranial; LMWH ¼ low-molecular weight heparin; PE ¼ pulmonary embolism; PTS ¼ postthrombotic syndrome; VKA ¼ vitamin K antagonist; VTE ¼ venous thromboembolism.

cost and the rate of MB of LMWH/VKA and apixaban in the first 3 months of treatment show the highest influence on the incremental costs. The variables with the highest impact on the incremental QALYs are the starting age, baseline utility value, and the risk of RecVTE in both treatment arms in the first cycle of the model. In all the univariate analyses the ICER remains cost-saving. Results of the PSAs from the societal and health care payer perspective are shown in the cost-effectiveness planes in Figure 4 and Supplemental Figure S3, respectively. Apixaban is 100% cost-effective compared with LMWH/VKA at a willingness to pay of €20,000/QALY, and 94% of the simulations indicate cost-savings.

Scenario Analyses The results of the scenario analyses are shown in Table V. In all scenarios, except one, the ICER

296

remains cost-saving. When treatment is extended to 18 months (scenario 2), the ICER is not cost-saving. The costs of apixaban compared with LMWH/VKA increase, but apixaban remains more effective, resulting in an ICER of €425/QALY. Similarly, a shorter treatment duration (scenario 1) saves more costs compared with the base-case analysis and is thereby still cost-saving. When anticoagulation-specific distribution of severity of the bleeding (scenario 3), obtained from the AMPLIFY trial, were applied to the model, the incremental costs were less, but the ICER was still cost-saving. Scenarios 4 and 5 have mainly influence on the incremental QALYs. Scenario 4 increases the health gain associated with apixaban treatment, whereas scenario 5 shows a decrease of the incremental QALYs. If applying the health care payer’s perspective (scenario 6), the incremental costs decrease, but the ICER remains cost-saving.

Volume 39 Number 2

L.A. de Jong et al.

DISCUSSION

Table IV. Outcomes per patient: incremental costs, QALYs, LYs, and the ICER. Variable

Our economic evaluation shows the cost-effectiveness of apixaban compared with LMWH/VKA for the acute treatment of VTE and the prevention of RecVTE in the Netherlands. The evaluation was done using a Markov model simulating 1,000 VTE patients receiving either apixaban or LMWH/VKA and was performed from a societal perspective.10 We found that the use of apixaban increases LYs/QALYs and reduces costs compared with LMWH/VKA; hence, apixaban is dominant over LMWH/VKA. The beneficial effect of apixaban on the health gain is mostly driven by the reduction in MB and CRNM bleeding but also by a small reduction (statistically not significant) in RecVTE events as observed in the AMPLIFY trial.8 Consequently, costs associated with these averted events may be prevented. The impact of the uncertainties in key input variables in the model on the robustness of the outcomes was assessed in several sensitivity and scenario analyses. The PSA found that apixaban is 100% cost-effective compared with LMWH/VKA at

LMWH/ VKA

Apixaban

Outcomes per patient Total QALYs 10.373 Total LYs 12.739 Total costs, € 8,178 Incremental results apixaban ΔQALYs ΔLYs ΔCosts, € ICER (per QALY gained)

10.330 12.700 8,414

0.044 0.039 –236 Costsaving Costsaving

ICER (per LY gained)

ICER ¼ incremental cost-effectiveness ratio; LY ¼ life year; QALY ¼ quality-adjusted life year.

Incremental costs (€) -400 Apixaban unit cost Rate MB LMWH/VKA (0-3 months) Rate MB apixaban (0-3 months)

-85

-236.33 -131

-342 -312

-161 -191

-283

-195

Administration cost

-277

Rate MB LMWH/VKA (3-6 months)

-277

-195

Acute care cost EC bleed

-275

-197

Rate MB apixaban (3-6 months)

-258

One off administration training cost

-260

-213

High value

Cost per fatal acute MB event

-258

-215

Low value

Acute care cost IC bleed

-257

-215

Starting age

-257

Maintenance cost IC bleed HR of mortality with IC bleeds

-253 -257

-207

-216 -224 -229

P of successful patient education

-248

-225

% IC bleeds amongst non-fatal MB

-248

-227

Figure 2. Tornado diagram illustrating the impact on the incremental costs from the univariate sensitivity analyses. The tornado diagram represents the impact of the 15 most influential variables on the incremental costs calculated in the univariate sensitivity analysis. The dark gray bars represent the high value of the 95% CI range of the variables, whereas the light gray bars represent the low value. The solid vertical line in the middle of the graph represents the base-case incremental costs. EC ¼ extracranial; IC ¼ intracranial; HR ¼ hazard ratio; LMWH ¼ low molecular weight heparin; MB ¼ major bleed; P ¼ probability; VKA ¼ vitamin K antagonist.

February 2017

297

Clinical Therapeutics Incremental QALYs 0,010

0,070

0.044 0,026

Starting age

0,059

0,021

Baseline utility value

0,053 0,056

0,031

Risk rVTE LMWH/VKA in the first cycle Risk rVTE apixaban in the first cycle

0,055

0,033 0,033

Rate MB LMWH/VKA (0-3 months)

0,054

0,032

Discount factor for health outcomes

0,049 High value

Risk rVTE apixaban in the second cycle

0,038

0,049

Risk rVTE LMWH/VKA in the second cycle

0,038

0,049

Rate MB apixaban (0-3 months)

0,038

0,049

Rate MB LMWH/VKA (3-6 months)

0,038

0,049

Low value

0,047

Rate MB apixaban (3-6 months)

0,040

% VTE related death amongst rVTE

0,041

Utility postacute IC bleeds

0,041

0,046

HR of morality for patients with DVT

0,041

0,046

0,047

Figure 3. Tornado diagram illustrating the impact on the incremental QALYs from the univariate sensitivity analyses. The tornado diagram represents the impact of the 15 most influential parameter uncertainty on the incremental QALYs calculated in the univariate sensitivity analysis. The dark gray bars represent the high value of the 95% CI range of the variables, whereas the light gray bars represent the low value. The solid vertical line in the middle of the graph represents the base-case incremental QALYs. DVT ¼ deep vein thromboembolism; HR ¼ hazard ratio; IC ¼ intracranial; LMWH ¼ low molecular weight heparin; MB ¼ major bleed; QALYs ¼ quality-adjusted life years; rVTE ¼ recurrent venous thromboembolism; VKA ¼ vitamin K antagonist; VTE ¼ venous thromboembolism.

Incremental costs

a willingness-to-pay threshold of €20,000/QALY; moreover, apixaban appeared to be cost-saving in 94% of the simulations. The univariate analyses found that apixaban unit costs and the rate of MB

had the most impact on the incremental costs, whereas the starting age and baseline utility value indicated the most impact on the incremental QALYs. The scenario analyses found that in all except

200

100 Incremental Outcome

-0,020

0 -0,000

0,020

0,040

0,060

0,080

0,100

-100

-200

-300

-400

-500

-600

Figure 4. Cost-effectiveness plane showing the results of the probabilistic sensitivity analysis of apixaban versus LMWH/VKA in the treatment and prevention of VTE from a societal perspective. LMWH ¼ low molecular weight heparin; QALY ¼ quality-adjusted life year; VKA ¼ vitamin K antagonist.

298

Volume 39 Number 2

L.A. de Jong et al.

Table V. Incremental costs, incremental QALYs, and the ICER in the scenario analyses. Scenario 1. 3-month treatment duration 2. 18-month treatment duration 3. Treatment-specific bleeding distribution vs LMWH/ VKA 4. LMWH/VKA RRs from third quartile of INR control 5. No treatment disutilities 6. Health care payer perspective

Incremental Cost, € Incremental QALY ICER, €/QALY –387.51 53.82 –131.39

0.041 0.127 0.054

Cost-saving 424.56 Cost-saving

–237.82 –236.23 –48.27

0.047 0.038 0.044

Cost-saving Cost-saving Cost-saving

ICER ¼ incremental cost-effectiveness ratio; INR ¼ international normalized ratio; LMWH ¼ low-molecular weight heparin; QALY ¼ quality-adjusted life years; RR ¼ relative risk; VKA ¼ vitamin K antagonist.

one scenario apixaban remains cost-saving compared with LMWH/VKA. The scenario in which the treatment was extended up to 18 months was the only not cost-saving scenario. It found that, although treating with apixaban is obviously associated with additional costs mainly due to the drug costs, it also results in an increase in QALYs. This resulted in an ICER of €425/ QALY. It is plausible that the longer the treatment, the less cost-effective apixaban becomes compared with LMWH/VKA. In the base-case analysis the distribution of the severity of MB (fatal/nonfatal) were equal for both treatments. In a scenario analysis this distribution was adapted to treatment-specific distributions found in the AMPLIFY trial. The equal distribution used in the base-case analysis can lead to an underestimation of the ICER, although in the scenario analysis the ICER was still cost-saving. To address the concern that the time in the therapeutic INR range in the Netherlands may be better than in the AMPLIFY study population (61%), a scenario analysis was based on the relative risks of the third quartile (TTR, 59.1%–68.0%) of the AMPLIFY patients receiving VKA.2,8 Although this third quartile indicated a lower RR of VTEs and VTEdies, the RR of MBs increased compared with the original study population. MBs are associated with very high event costs; therefore, apixaban was, again, costsaving compared with LMWH/VKA. Annual medical reports of the Dutch Thrombotic Services suggest that the TTR may be even higher than 68%.2 Contrarily, the target INR range in the Netherlands (2.0–3.5) is

February 2017

wider than the target INR range used in the trials (2.0–3.0), causing an overestimation of the TTR in the Netherlands.2,8 Although lower VTE and MB rates in the subgroup TTR 4 68% (fourth quartile) were expected, this was not found in the trial; therefore, this scenario was not conducted.8 Finally, the scenario analysis from the health care payer perspective was also cost-saving. The most recent update of the Dutch guidelines for pharmacoeconomic evaluations states that all indirect costs have to be included in the economic model.44 However, currently these costs are not often included. In this study we therefore investigated 2 perspectives, namely the societal and the health care payer perspective. Note that this is not applicable on a more marketbased system, such as in the United States. Next to the uncertainties and limitations tested in the sensitivity and scenario analyses, the model had some other limitations. First, it is assumed that all patients with an IC bleeding and none of the non-MB patients discontinued anticoagulation therapy. In practice this is decided on the patient’s individual characteristics. Furthermore, switching to other treatment is often seen in practice, but this was not included in the model. These assumptions can both lead to overestimation and underestimation of the ICER. To our knowledge this is the first cost-effectiveness analysis of apixaban for the treatment and prevention of VTE in the Netherlands. Previously, a Canadian study estimated the economic benefits of the extended treatment for the treatment and prevention of VTE

299

Clinical Therapeutics with apixaban compared with LMWH/VKA. The analysis was based on the results of the AMPLIFY and AMPLIFY-EXT trials and resulted in an ICER of $4,828 per QALY gained.44 The economic evaluation also found the cost-effectiveness of apixaban compared with other DOACs, which is mostly driven by the reduction of bleeding associated with apixaban use. Same results were found in an evaluation from the US payer perspective by Amin et al,45 who compared the incremental medical costs of apixaban, dabigatran, rivaroxaban, and edoxaban with LMWH/ VKA in VTE patients. Apixaban appeared to have the greatest reduction of medical costs, also driven by the bleeding reduction found in the AMPLIFY trial. Jurgin et al46 compared the cost-effectiveness of dabigatran and rivaroxaban for the treatment and extended anticoagulation in settings in the United Kingdom, showing dabigatran to be dominant over rivaroxaban due to higher clinical benefits and lower treatment costs. The international literature seems in line with our findings. Differences are expected across different studies because some country-specific data can slightly alter model preferences and subsequently the results.

CONCLUSIONS Apixaban was found to be cost-saving in the basecase, univariate sensitivity and most of the scenario analyses. The only not cost-saving scenario, in which an 18-month treatment duration was applied, is still highly cost-effective. The PSA found that apixaban is cost-saving in 94% of the simulations, compared with LMWH/VKA. In conclusion, the economic evaluation shows that apixaban is a cost-effective alternative compared with the current standard of care of LMWH/VKA for the treatment of VTE and prevention of RecVTE in the Netherlands.

ACKNOWLEDGMENTS We thank Mark Rozenbaum from Pfizer NL for his input during this research.

AUTHOR CONTRIBUTIONS L.A. de Jong: literature search, validation of the model, adaptation of the model, study design, data interpretation, writing. E. Dvortsin: data interpretation, writing. K.J. Janssen: study design, literature

300

search. M.J. Postma: data interpretation, writing, model validation.

CONFLICTS OF INTEREST This study was funded by Bristol-Myers Squibb. Professor Dr. Maarten Postma has received various research grants from various pharmaceutical companies, including but not limited to Pfizer, Bristol-Myers Squibb, GSK, Roche, and Novartis. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

SUPPLEMENTAL MATERIAL Supplemental tables and figures accompanying this article can be found in the online version at http:// dx.doi.org/10.1016/j.clinthera.2016.12.012.

REFERENCES 1. Oudega R, Van Weert H, Stoffers HEJH, et al. NHGStandaard Diepe veneuze trombose en longembolie (eerste herziening). NHG-werkgroep Diepe veneuze trombose en longembolie. Huisarts Wet. 2015;58:26–35. 2. Federation Dutch Thrombotic Services (FNT). Samenvatting Medische Jaarverslagen 2014. http://www.fnt.nl/me dia/docs/FNT_Samenvatting_Medisch_JV_2014.pdf. [Accessed September 2015]. 3. Kwaliteitsinstituut voor de Gezondheidszorg CBO i.s.m. Nederlands Huisartsen Genootschap NHG. Richtlijn Diagnostiek, Preventie, en Behandeling van Veneuze Trombo-embolie en Secundaire Preventie Arteriële Trombose. Utrecht: CBO; 2008. 4. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7. 5. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829–1836. 6. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386–1389. 7. Werth S, Breslin T, Niainle F, Beyer-Westendorf J. Bleeding risk, management and outcome in patients receiving nonVKA oral anticoagulants (NOACs). Am J Cardiovasc Drugs. 2015;15:235–242. 8. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.

Volume 39 Number 2

L.A. de Jong et al. 9. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. 10. Instructions for costs research in Dutch Health settings. 2016. https://www.zorginstituutnederland. nl/over-ons/publicaties/publicatie/ 2016/02/29/richtlijn-voor-het-uit voeren-van-economische-evaluatie s-in-de-gezondheidszorg. [Accessed September 2015]. 11. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. 1st edition. Oxford University Press; 2006. 12. Stevanovic J, de Jong LA, Kappelhoff BS, et al. Dabigatran for the treatment and secondary prevention of venous thromboembolism; a costeffectiveness analysis for the Netherlands. PlosOne. 2016;11:e0163550. 13. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199–205. 14. Linkins L, O'Donnell M, Julian JA, Kearon C. Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost. 2010;8: 2201–2207. 15. Ariesen M, Claus S, Rinkel G, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060–2065. 16. Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine. 2006; 85:253–262. 17. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423–428.

February 2017

18. Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012;9:e1001155. 19. Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, et al. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2010;8: 2575–2577. 20. Ng AC, Chung T, Yong AS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes. 2011;4:122–128. 21. Statistics Netherlands website. Life-expectancy; gender and age, from 1950 (per year). http://statline.cbs.nl/Stat web/publication/?DM=SLNL&PA= 37360ned&D1=0&D2=a&D3=20-99 &D 4 = l &H D R = G 1, T &S T B = G 2 , G3&VW=T. [Accessed October 2015]. 22. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–741. 23. Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost. 2004;92: 1336–1341. 24. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319–329. 25. Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800–804. 26. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49–56.

27. National Institute of Health and Care Excellence (NICE). Venous thromboembolism: reducing the risk for patients in hospital. 2010. NICE CG92. 28. Hogg K, Kimpton M, Carrier M, et al. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173:1067–1072. 29. Z-index. www.medicijnkosten.nl. [Accessed September 2015]. 30. NZA tarievenlijst. Version 2012. 31. Stevanović J, Pompen M, Le HH, et al. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS ONE. 2014;9: e103974. 32. National Institute for Health and Care Excellence (NICE). Final appraisal determination – Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. Issue date: April 2013. https://www.nice.org.uk/guid ance/TA287/documents/pulmonar y-embolism-acute-treatment-vte-pre vention-rivaroxaban-final-appraisaldetermination-document2. [Accessed September 2015]. 33. National Institute for Health and Care Excellence (NICE). Final appraisal determination – Final appraisal determination – Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Issue date: May 2013. https://www.nice.org.uk/guid ance/ta261/resources/venous-throm boembolism-treatment-and-long-termsecondary-prevention-rivaroxaban-fina l-appraisal-determination-guidance2. [Accessed September 2015]. 34. Ten Cate‐Hoek A, Toll D, Büller H, et al. Cost‐effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost. 2009;7:2042–2049. 35. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek iMTA geactualiseerde versie. Dutch Cost Manual. 2010.

301

Clinical Therapeutics 36. Den Haag/Heerlen. Central Institute of Statistics Web site. http://stat line.cbs.nl. [Accessed September 2015]. 37. Guanella R, Ducret T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost. 2011;9:2397–2405. 38. Canadian Drug Expert Committee (CDEC). Apixaban for the treatment of venous thromboembolic events (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) and prevention of recurrent DVT and PE, for a duration of up to six months. Issue date: April 2015. Available from: https://www. cadth.ca/sites/default/files/cdr/com plete/cdr_complete_SR0397_EliquisVTE_May-11-15.pdf. [Accessed October 2015]. 39. GSK Professionals. Fraxodi dosage advice, prevention and treatment. http://professionals.gsk.nl/content/ dam/Health/nl_NL/HCP_Home/ther apiegebieden/Trombose/documents/ nl-trombose-dosagecard.pdf. [Accessed September 2015]. 40. Dutch Federation for Thrombotic Services. 2010. http://www.fnt.nl/ media/docs/jaarverslagen/Jaarver slag_FNT_Medisch_2010.pdf. [Accessed September 2015]. 41. Key Opinion Leader: Medical professor in one of the University Medical Centers in the Netherlands with over 20 years experience in the diagnosis and treatment of venous thromboembolism. 42. Inflation Statistics Netherlands. http://statline.cbs.nl/Statweb/publi cation/?DM=SLN L&PA=70936 NED&D1=0&D2=662,675,682-684 &HDR=T&STB=G1&VW=T. [Accessed October 2015]. 43. NZA. Version. Dutch guidelines for pharmaco-economic research. 2015. 44. Quon P, Le HH, Raymond V, et al. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention

302

of recurrent venous thromboembolism in Canada. J Med Econ. 2016;19: 557–567. 45. Amin A, Jing Y, Trocio J, et al. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism

patients. J Med Econ. 2014;17:763– 770. 46. Jugrin AV, Hösel V, Ustyugova A, et al. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting. J Med Econ. 2015;19:1–10.

Address correspondence to: Lisa A. de Jong, MSc, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. E-mail: l.a.de.jong@student. rug.nl

Volume 39 Number 2

L.A. de Jong et al.

SUPPLEMENTARY MATERIAL

Included

Eligibility

Screening

Identification

See Figures S1–S3. See Tables SI–SIII.

Records identified through database searching (n = 389 )

Additional records identified through reference list screening (n = 6 )

Records screened (n = 35 )

Full-text articles assessed for eligibility (n = 13 )

Records excluded (n = 354 )

Full-text article excluded, with reasosns: Out dated article (n = 1) Utilities not suitable for model (n = 4)

Included references for the utility parameters (n = 8 ) [22-29]

Figure S1. PRISMA flow diagram summarizing the systematic literature search for utility scores. Different combinations of the search terms ‘utility’, ‘venous thromboembolism’, ‘quality of life’, ‘apixaban’ and ‘EQ-5D’ were used. Reference numbers refer to the main body text. n: number of records.

February 2017

302.e1

Records identified through database and Google searching (n = 562 )

Screening

Identification

Clinical Therapeutics

Additional records identified through other reference list scanning (n = 4)

Records excluded (not relevant for this reseach (n = 52)

Records screened (n = 73 )

Eligibility Included

8 references excluded, with reasons: Wrong indication (n=5) Irrelevant study population (n=2) Not covering information on cost parameter n=1

References assessed for eligibility (n = 21 )

Included references for cost parameter (n = 13 ) [30-41,43]

Figure S2. PRISMA flow diagram summarizing systematic literature search. In the electronic search we used various combinations of the terms ‘cost’, ‘kosten’, ‘NOAC’, ‘cost-effectiveness’, ‘apixaban’, ‘VKA’, ‘veneuze tromboembolie’ and ‘venous thromboembolism’. Reference numbers refer to the main body text. n: number of records.

Incremental costs

200

100

Incremental Outcome -0,020

0 0,000

0,020

0,040

0,060

0,080

0,100

0,120

-100

-200

-300

Figure S3. Cost-effectiveness plane showing the results of the probabilistic sensitivity analysis of apixaban versus LMWH/VKA in the treatment and prevention of VTE from a healthcare payer perspective. QALYs, quality-adjusted life years.

302.e2

Volume 39 Number 2

L.A. de Jong et al.

Table SI. Patient characteristics of the AMPLIFY trial, used in the Markov model. Characteristic

Value

Age (years) Male sex (%) Weight Mean (kg) Distribution (%) r 60 kg 60 - 100 kg Z 100 kg Data missing DVT (%) PE (%)

56.9 58.7 84.6 8.8 71.7 19.3 0.2 65.8 34.2

DVT, deep venous thromboembolism; PE, pulmonary embolism

Table SII. Utilities applied in the Markov model. Reference numbers refer to the main body text. IC, intracranial; CTEPH, chronic thromboembolic pulmonary hypertension; PE, pulmonary embolism; DVT, deep venous thromboembolism; CRNM, clinically relevant non-major; PTS, post-thrombotic syndrome; NICE, National Institute for Health and Care Excellence; LMWH, low-molecular weight heparin; VKA, vitamin K antagonist. Utilities

Value

Baseline utility Post-IC bleeding state Post-CTEPH state Utility decrements PE DVT Non-IC bleeding CRNM bleeding Severe PTS Anticoagulation Apixaban LMWH/VKA

0.825 0.330 0.650 Value 0.32 0.11 0.30 0.0054 0.070

[22] [23] [24] [23] [23] [23] [25] [27]

Duration 30 days 30 days 30 days 2 days Throughout

0.002 0.013

[28] [28]

Whilst on treatment Whilst on treatment

February 2017

Source

Source [27], [28] [27], [28] [27], [28] Assumption [26] [5] [5]

302.e3

Clinical Therapeutics

Table SIII. Overview of scenario analyses. VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep venous thromboembolism; CRNM, clinically relevant non-major bleeding; LMWH, lowmolecular weight heparin; VKA, vitamin K antagonist; IC, intracranial; INR, international normalized ratio; RR, relative risk. References refer to the main body text. Scenario 1: treatment duration 3 months Difference to base case: transition probabilities between 3-6 months disregarded and costs of 3 months treatment (versus 6 months in base case) Scenario 2: treatment duration 12 months Sources Risk of recurrent VTE and VTE related death Apixaban 6-9 months 0.0048 (0.0001-0.0094) [9] Apixaban 9-12 months 0.0059 (0.0007-0.0111) [9] No treatment 6-9 months 0.0277 (0.0166-0.0389) [9] No treatment 9-12 months 0.0265 (0.0156-0.0375) [9] Distribution of PE, DVT and VTE related death 4 6 months VTE related death 0.1188 [9] Recurrent PE 0.2475 [9] Recurrent DVT 0.6337 [9] Risk of major bleeding Apixaban 4 6 months 0.0024 (0.0000-0.0057) [9] No treatment 4 6 months 0.0048 (0.0001-0.0096) [9] Risk of CRNM bleeding Apixaban 4 6 months 0.03 (0.0182-0.0412) [9] No treatment 4 6 months 0.023 (0.0128-0.0332) [9] Risk of other treatment discontinuation (unrelated to discontinuation due to the events modelled) Apixaban 4 6 months 0.0667 (0.0498-0.0835) [9] No treatment 4 6 months Not applicable Scenario 3: treatment specific distribution of fatal major bleeding and non-fatal IC bleeding % Fatal major bleeding Apixaban 0.0667 [8] LMWH/VKA 0.0408 [8] % Non-Fatal IC bleeding Apixaban 0.2143 [8] LMWH/VKA 0.1224 [8] Scenario 4: Efficacy and safety from third quartile of INR control (RR LMWH/VKA vs apixaban) RR recurrent VTE 1.33 (versus 1.19 in base case) [8] RR major bleeding 3.02 (versus 3.33 in base case) [8] Scenario 5: No decrements for LMWH/VKA or apixaban treatment Difference to base case: decrements -0.013 for LMWH/VKA and -0.002 for apixaban treatment Scenario 6: Health care payer perspective Difference to base case: travel expenses and productivity excluded from the analysis

302.e4

Volume 39 Number 2